200 related articles for article (PubMed ID: 34694680)
1. Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing.
Onoufriadis A; Proudfoot LE; Ainali C; Torre D; Papanikolaou M; Rayinda T; Rashidghamat E; Danarti R; Mellerio JE; Ma'ayan A; McGrath JA
Exp Dermatol; 2022 Mar; 31(3):420-426. PubMed ID: 34694680
[TBL] [Abstract][Full Text] [Related]
2. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
[TBL] [Abstract][Full Text] [Related]
3. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.
Woodley DT; Cogan J; Hou Y; Lyu C; Marinkovich MP; Keene D; Chen M
J Clin Invest; 2017 Aug; 127(8):3028-3038. PubMed ID: 28691931
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of chronicity signatures in fibroblasts isolated from recessive dystrophic epidermolysis bullosa chronic wound dressings under culture conditions.
De Gregorio C; Catalán E; Garrido G; Morandé P; Bennett JC; Muñoz C; Cofré G; Huang YL; Cuadra B; Murgas P; Calvo M; Altermatt F; Yubero MJ; Palisson F; South AP; Ezquer M; Fuentes I
Biol Res; 2023 May; 56(1):23. PubMed ID: 37161592
[TBL] [Abstract][Full Text] [Related]
5. Pathomechanisms of Altered Wound Healing in Recessive Dystrophic Epidermolysis Bullosa.
Cianfarani F; Zambruno G; Castiglia D; Odorisio T
Am J Pathol; 2017 Jul; 187(7):1445-1453. PubMed ID: 28460207
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts.
Condorelli AG; Logli E; Cianfarani F; Teson M; Diociaiuti A; El Hachem M; Zambruno G; Castiglia D; Odorisio T
Br J Dermatol; 2019 Nov; 181(5):1017-1027. PubMed ID: 30816994
[TBL] [Abstract][Full Text] [Related]
7. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.
So JY; Nazaroff J; Iwummadu CV; Harris N; Gorell ES; Fulchand S; Bailey I; McCarthy D; Siprashvili Z; Marinkovich MP; Tang JY; Chiou AS
Orphanet J Rare Dis; 2022 Oct; 17(1):377. PubMed ID: 36253825
[TBL] [Abstract][Full Text] [Related]
9. Collagen VII Expression Is Required in Both Keratinocytes and Fibroblasts for Anchoring Fibril Formation in Bilayer Engineered Skin Substitutes.
Supp DM; Hahn JM; Combs KA; McFarland KL; Schwentker A; Boissy RE; Boyce ST; Powell HM; Lucky AW
Cell Transplant; 2019; 28(9-10):1242-1256. PubMed ID: 31271052
[TBL] [Abstract][Full Text] [Related]
10. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
[TBL] [Abstract][Full Text] [Related]
11. Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa.
Tartaglia G; Cao Q; Padron ZM; South AP
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065916
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
Hong SA; Kim SE; Lee AY; Hwang GH; Kim JH; Iwata H; Kim SC; Bae S; Lee SE
Mol Ther; 2022 Aug; 30(8):2664-2679. PubMed ID: 35690907
[TBL] [Abstract][Full Text] [Related]
13. Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa.
Atanasova VS; Jiang Q; Prisco M; Gruber C; Piñón Hofbauer J; Chen M; Has C; Bruckner-Tuderman L; McGrath JA; Uitto J; South AP
J Invest Dermatol; 2017 Sep; 137(9):1842-1849. PubMed ID: 28549954
[TBL] [Abstract][Full Text] [Related]
14. Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa.
Cogan J; Weinstein J; Wang X; Hou Y; Martin S; South AP; Woodley DT; Chen M
Mol Ther; 2014 Oct; 22(10):1741-52. PubMed ID: 25155989
[TBL] [Abstract][Full Text] [Related]
15. A novel homozygous splice site mutation in COL7A1 in a Chinese patient with severe recessive dystrophic epidermolysis bullosa and squamous cell carcinoma.
Huang L; Wong YP; Burd A
Int J Dermatol; 2011 Jan; 50(1):52-6. PubMed ID: 21182502
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with recessive dystrophic epidermolysis bullosa in the Netherlands: expansion of the mutation database and unusual phenotype-genotype correlations.
van den Akker PC; van Essen AJ; Kraak MM; Meijer R; Nijenhuis M; Meijer G; Hofstra RM; Pas HH; Scheffer H; Jonkman MF
J Dermatol Sci; 2009 Oct; 56(1):9-18. PubMed ID: 19665875
[TBL] [Abstract][Full Text] [Related]
17. Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa.
Ebens CL
EMBO Mol Med; 2021 Oct; 13(10):e14864. PubMed ID: 34515407
[TBL] [Abstract][Full Text] [Related]
18. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Eichstadt S; Barriga M; Ponakala A; Teng C; Nguyen NT; Siprashvili Z; Nazaroff J; Gorell ES; Chiou AS; Taylor L; Khuu P; Keene DR; Rieger K; Khosla RK; Furukawa LK; Lorenz HP; Marinkovich MP; Tang JY
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578311
[TBL] [Abstract][Full Text] [Related]
19. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
Gurevich I; Agarwal P; Zhang P; Dolorito JA; Oliver S; Liu H; Reitze N; Sarma N; Bagci IS; Sridhar K; Kakarla V; Yenamandra VK; O'Malley M; Prisco M; Tufa SF; Keene DR; South AP; Krishnan SM; Marinkovich MP
Nat Med; 2022 Apr; 28(4):780-788. PubMed ID: 35347281
[TBL] [Abstract][Full Text] [Related]
20. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.
Twaroski K; Eide C; Riddle MJ; Xia L; Lees CJ; Chen W; Mathews W; Keene DR; McGrath JA; Tolar J
Br J Dermatol; 2019 Dec; 181(6):1247-1253. PubMed ID: 30924923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
